Pembrolizumab Shows Promising Activity in Mismatch Repair–Deficient CRC

June 3-7, 2016; Chicago, Illinois
Updated data in patients with mismatch repair–deficient metastatic CRC show potential association with treatment response to pembrolizumab.
Format: Microsoft PowerPoint (.ppt)
File Size: 501 KB
Released: June 9, 2016

Acknowledgements

This activity is supported by educational grants from
Amgen
Ariad Pharmaceuticals
Bayer HealthCare Pharmaceuticals Inc.
Celgene Corporation
Genentech
Incyte
Merck & Co., Inc.
Taiho Pharmaceuticals

Related Content

Expert review of key data in GI cancers from the 2022 ASCO Annual Meeting, from Clinical Care Options (CCO)

Christopher H. Lieu, MD Rachna Shroff, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: August 31, 2022 Expired: August 30, 2023

Expert commentary on biomarker testing and targeted treatment for gastrointestinal cancers, from Clinical Care Options (CCO)

John L. Marshall, MD Michael J. Pishvaian, MD, PhD Manish A. Shah, MD Released: August 22, 2022

Download this slideset by Madeline Deutsch, MD, MPH, presenting culturally appropriate strategies to maximize preventive care in transgender people from Clinical Care Options (CCO)

person default Madeline Deutsch, MD, MPH Released: August 22, 2022

Madeline Deutsch, MD, MPH, discusses culturally appropriate strategies to maximize preventive care for transgender people, including CV risk and cancer screening from Clinical Care Options (CCO)

person default Madeline Deutsch, MD, MPH Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: August 22, 2022 Expired: August 21, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings